Lonza Group Ltd
LONN: XSWX (CHE)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| >yC | LOCK|kL$%N | LOCK|yjRGt% |
Lonza Earnings: Strong Demand for Outsourced Drug Manufacturing Supports Long-Term Growth
Lonza delivered 19% constant-currency sales growth and core EBITDA margin of nearly 30% in the first half of 2025.
